Published 3 days ago • loading... • Updated 3 days ago

Breakthrough Study: Pancreatic Cancer Survival in Young Patients Linked to TGFB2 Biomarker, Shows 49-Month Difference

Clinical study reveals TGFB2 biomarker predicts 67-month vs 18-month survival in young pancreatic cancer patients. Supports OT-101 drug development. See full data.

This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.

2 Articles

ADKhabar

Oncotelic Therapeutics Highlights PeerReviewed Publication Linking TGFB2 to Survival in Younger Pancreatic Cancer Patients

Data support further evaluation of investigational antisense OT‑101 (trabedersen) as a TGFB2‑targeted approach in pancreatic ductal adenocarcinoma (PDAC). AGOURA HILLS, Calif., July 17, 2025 (GLOBE NEWSWIRE) — Oncotelic Therapeutics, Inc. (OTCQB: OTLC) (“Oncotelic” or the “Company”), a clinical‑stage biopharmaceutical company developing RNA‑targeted and small‑molecule therapeutics for cancer and rare diseases, today highlighted the publication o…

3 days ago

Read Full Article

stocktitan.net

Breakthrough Study: Pancreatic Cancer Survival in Young Patients Linked to TGFB2 Biomarker, Shows 49-Month Difference

Clinical study reveals TGFB2 biomarker predicts 67-month vs 18-month survival in young pancreatic cancer patients. Supports OT-101 drug development. See full data.

3 days ago

Read Full Article

Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/year

Stories disproportionately reported by the Left or the Right